GSK (LSE:GSK) has been on investor radars after recent trading performance, with the share price showing a 1.1% decline over ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value ...

Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's ...

GSK has agreed to acquire Rapt Therapeutics, a US-based biotech whose leading drug combats food allergies, in a deal that ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain for ...

The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.

GSK shares rose to the top of the FTSE 100 leader board after the drugmaker raised its 2025 guidance on the back of a strong third-quarter performance. The earnings were the last to be presented by ...

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

The acquisition was announced on Tuesday, News.Az reports, citing Reuters. This marks GSK's first major purchase under the ...

British biopharma major GSK to acquire US-based biopharma company RAPT Therapeutics via a $2.2 billion deal. Here's what ...

GSK plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and ...